Maximus (NYSE:MMS) Rating Increased to Outperform at Raymond James

Maximus (NYSE:MMS) was upgraded by stock analysts at Raymond James from a “market perform” rating to an “outperform” rating in a research report issued to clients and investors on Thursday, MarketBeat reports. The firm presently has a $90.00 target price on the health services provider’s stock. Raymond James’ price target would suggest a potential upside of 20.56% from the stock’s previous close.

Separately, StockNews.com cut shares of Maximus from a “buy” rating to a “hold” rating in a report on Friday, December 27th.

Maximus Stock Up 0.6 %

MMS stock opened at $74.65 on Thursday. The company has a market cap of $4.50 billion, a price-to-earnings ratio of 14.93 and a beta of 0.73. Maximus has a twelve month low of $69.72 and a twelve month high of $93.97. The business has a 50 day moving average price of $78.18 and a two-hundred day moving average price of $85.41. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.59.

Insider Activity

In other Maximus news, CEO Bruce Caswell purchased 3,500 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The shares were acquired at an average cost of $70.64 per share, for a total transaction of $247,240.00. Following the completion of the purchase, the chief executive officer now owns 275,929 shares of the company’s stock, valued at approximately $19,491,624.56. The trade was a 1.28 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Michelle F. Link sold 2,208 shares of Maximus stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $73.83, for a total transaction of $163,016.64. Following the completion of the sale, the insider now owns 6,567 shares of the company’s stock, valued at $484,841.61. This trade represents a 25.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have purchased 7,063 shares of company stock valued at $502,017 over the last ninety days. 1.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Maximus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MMS. JPMorgan Chase & Co. grew its holdings in shares of Maximus by 8.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 223,766 shares of the health services provider’s stock worth $20,846,000 after purchasing an additional 18,143 shares in the last quarter. Tidal Investments LLC grew its stake in Maximus by 49.1% during the third quarter. Tidal Investments LLC now owns 20,674 shares of the health services provider’s stock worth $1,926,000 after buying an additional 6,809 shares in the last quarter. Wilmington Savings Fund Society FSB increased its holdings in Maximus by 3.3% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 66,805 shares of the health services provider’s stock valued at $6,224,000 after buying an additional 2,164 shares during the period. World Investment Advisors LLC raised its position in shares of Maximus by 6.6% in the 3rd quarter. World Investment Advisors LLC now owns 5,289 shares of the health services provider’s stock valued at $493,000 after buying an additional 326 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Maximus during the 3rd quarter worth approximately $319,000. 97.21% of the stock is owned by institutional investors and hedge funds.

Maximus Company Profile

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.